ANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLP

Group 1 - Anika Therapeutics, Inc. is under investigation by Kirby McInerney LLP for potential violations of federal securities laws or unlawful business practices by the company or its senior management [1] - On July 30, 2025, Anika announced topline results from its clinical trial of Hyalofast, which showed improvements in treated patients but did not meet pre-specified co-primary endpoints due to a higher dropout rate and missed visits during COVID [2] - Following the announcement, Anika's share price fell by $3.06, approximately 27.42%, closing at $8.10 per share on the same day [2] Group 2 - Investors who purchased or acquired Anika securities and have information regarding the investigation are encouraged to contact Kirby McInerney LLP for further discussion about their rights or interests [3] - Kirby McInerney LLP specializes in securities litigation and has achieved recoveries totaling billions of dollars for shareholders [4]